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| INTRODUC TI ON
Metastatic BC is one of the most aggressive malignancies and remains extremely challenging to treat. Cisplatin-based combination chemotherapy has been the gold standard first-line treatment for metastatic BC. 1, 2 However, the initial response rate and median overall survival were previously reported to be low at approximately 60% and 13-14 months, respectively. 1 Furthermore, CDDP has been reported to cause severe side-effects. Therefore, a new therapeutic strategy for the treatment of metastatic BC is strongly warranted.
Cancer stem cells, which possess stem cell-like characteristics, including multilineage and self-renewal potentials, have been identified in cancer tissues. 3 Previous studies reported that tumor progression, metastasis, and resistance to anticancer therapy were driven by CSCs, which were identified by cell surface markers such as CD44. [4] [5] [6] [7] CD44 exists in numerous variant isoforms generated through the alternative mRNA splicing of different combinations of 10 exons (v1-10), and the variant isoforms of CD44 containing v8-v10 (CD44v9) have been identified as new cell surface markers of CSCs. 8 In the field of urothelial carcinoma, CD44v9 expression has been associated with poor prognosis and chemoresistance. [9] [10] [11] [12] CD44v9 on the cell surface stabilizes xCT, which is a subunit of the cystine transporter that modulates its function. xCT acts as an Na + -independent transporter mediated by the exchange of extracellular cystine for intracellular glutamate, which promotes the synthesis of GSH and subsequently reduces ROS production. Therefore, the interaction between CD44v9 and xCT contributes to the features of CSCs, such as metastasis and resistance to anticancer therapy.
We focused on SSZ, an anti-inflammatory drug approved for the treatment of inflammatory bowel disease and rheumatoid arthritis. 13 Sulfasalazine is an inhibitor of xCT-mediated cystine transporters 14 and exerts inhibitory effects against tumor growth, invasion, and metastasis in many types of cancers. 4, [15] [16] [17] [18] [19] Furthermore, previous studies reported that SSZ enhanced the effects of CDDP therapy. 20, 21 However, limited information is currently available on the functional role of SSZ, which could modulate the CD44v9-xCT system in order to enhance CDDP-induced cytotoxicity and inhibit the metastatic potential of BC.
In the present study, we investigated: (a) the prognostic role of CD44v9 for disease recurrence and cancer-specific death in MIBC patients who underwent RC; (b) the functional role of SSZ in ROS production and its cytotoxic effects on MBT-2V cells, which were established from a parent MBT-2 tumor with multiple lung metastases; 22 and (c) the therapeutic effects of SSZ with or without CDDP using an MBT-2V lung metastatic BC model.
| MATERIAL S AND ME THODS

| Cell culture, agents, and animals
MBT-2V cells were established and characterized from the parent MBT-2 cells by Lerner Research Institute, Cleveland Clinic Foundation (Cleveland, OH, USA). 22 MBT-2V cells were maintained in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) with 10%
FBS at 37°C in a humidified 5% CO 2 atmosphere. Sulfasalazine, NAC, BSO, and CDDP were purchased from Sigma-Aldrich (St. Louis, MO, USA). Eight-week-old female C3H/HeN mice were purchased from CLEA Japan (Tokyo, Japan). Mice were maintained under standardized laboratory conditions with free access to food and water. 
| Tissue samples
| Immunohistochemistry
Four-micrometer-thick paraffin sections from cystectomy specimens were deparaffinized in xylene and dehydrated in a graded ethanol series. After antigen retrieval with citric acid (pH = 6.0) at 120°C for 10 minutes, endogenous peroxidase activity was blocked with 1% hydrogen peroxide for 20 minutes followed by washing with distilled water. In order to bind nonspecific antigens, sections were incubated at room temperature for 15 minutes with 5% skim milk in PBS. Sections were then incubated at 4°C overnight with an anti-CD44v9 rat mAb (1:5000 dilution; Cosmo Bio, Tokyo, Japan).
After washing with PBS, tissue sections were incubated with an anti-rat goat secondary Ab (Histofine Simple Stain MAX PO (rat);
Nichirei Biosciences, Tokyo, Japan) for 30 minutes. The Ab was detected using the avidin-biotin complex peroxidase method. Color was developed with 3,30-diaminobenzidine tetrahydrochloride in 50 mmol/L Tris-HCl (pH 7.5) containing 0.005% hydrogen peroxide.
Sections were then counterstained with hematoxylin.
The results of CD44v9 immunostaining in RC specimens were evaluated as described previously. 9 In order to assess CD44v9 stain- 
| Survival analysis for 63 patients who underwent RC
The relationship between CD44v9 expression and clinicopathological features was assessed using the χ 2 test. Recurrence-free survival was defined as the time from RC until the presence of local recurrence and/ or distant metastases. Cancer-specific survival was defined as the time from RC until death due to BC. Both RFS and CSS rates were estimated using the Kaplan-Meier method and compared with the log-rank test.
Univariate and multivariate Cox regression analyses were carried out in order to assess prognostic indicators for disease recurrence and survival. Only significant parameters detected in the univariate analysis were included in the final multivariate analysis using Cox's proportional hazards regression models with stepwise forward selection. The level of significance was set at P < .05. These analyses were undertaken with the SPSS version 23.0 statistical software package (IBM, Somers, NY, USA).
| Cell proliferation assay
MBT-2V cells were seeded on 96-well black plates in a volume of 
| Measurement of GSH and ROS levels
Intracellular GSH levels were examined using a GSH-Glo Glutathione Reagent (Promega) was added to the wells and incubated for 15 minutes. The luminescence signal was detected using an Enspire 2300.
The experiment was carried out in triplicate, and data were expressed as the mean ± SE of intracellular GSH concentrations.
Intracellular ROS levels were assessed using dichlorodihydro- 
| Cell extraction and western blot analysis
In order to obtain whole cell extracts, we used RIPA buffer consisting of 50 mmol/L Tris-HCl (pH 7.5), protease inhibitor, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, and 150 mmol/L NaCl.
In western blotting, 20 μg total protein from each sample was loaded onto 12.5% SDS-polyacrylamide gels and transferred to a nitro- . Signal intensities were quantified using the LAS 4000 system (GE Healthcare). The experiment was carried out in triplicate, and data were expressed as the mean ± SE of the relative signal intensities.
| In vivo experiment
All animal experiments were reviewed and approved by our In order to assess the potential toxicity of SSZ, we undertook laboratory tests for creatinine, aspartate transaminase, and alanine transaminase and investigated the histological appearance of the major organs, including the heart, liver, kidneys, spleen, pancreas, and ovaries.
| RE SULTS
| CD44v9 expression in 63 patients with MIBC
The mean ± SE of the density of CD44v9 expression was 16.5 ± 26.9%. We used a cut-off level of 5%, the median of the density of CD44v9 expression. Based on the cut-off level of 5%, patients were classified into high (n = 36, 57.1%) and low CD44v9 expression groups (n = 27, 42.9%). Representative CD44v9 immunohistochemical staining is shown in Figure 1A -C. Low and high CD44v9 expression in tumor specimens are shown in Figure 1A ,B, respectively. In Figure 1C , showing the high-power field of Figure Table 2) . A multivariate Cox regression analysis showed that high CD44v9 expression in tumor specimens (HR 6.18, P = .016) was independently associated with disease recurrence in addition to pN1 or greater tumors (HR 3.19, P = .036).
Cancer-specific death was noted in 14 patients (22.2%) during the follow-up: 13 in the high CD44v9 expression group and 1 in the low CD44v9 expression group. A Kaplan-Meier curve revealed that the 5-year CSS rate of the high CD44v9 expression group was 59.8%, which was significantly lower than that of the low CD44v9 expression group (95.2%, P = .003, Figure 1E) . A univariate Cox analysis identified sex (P = .037), pathological T stage (P = .011), pathological N stage (P = .004), and CD44v9 expression in tumor specimens (P = .003) as significant prognostic factors for cancer-specific death (Table 2) . A multivariate Cox regression analysis revealed that only high CD44v9 expression in tumor specimens (HR 5.67, P = .031) was independently associated with cancer-specific death.
| Effects of SSZ on cytotoxicity and function of the CD44v9-xCT system in MBT-2V cells
We initially assessed the cytotoxic effects of various concentrations of SSZ in MBT-2V cells (Figure 2A) . The means ± SE of relative cell viability in MBT-2V cells treated with 300, 400, 500, or 600 μmol/L SSZ were 86.8 ± 7.8%, 20.7 ± 7.2%, 6.1 ± 11.4%, and 3.5 ± 7.9%, respectively. 1.6 ± 5.4%, which were significantly lower than those in MBT-2V cells treated with 400, 600, or 800 μmol/L SSZ in addition to 3 μM NAC (108.5 ± 7.3%, 109.6 ± 7.8%, and 78.9 ± 5.4%, respectively, P < .001 for each).
We then confirmed whether the SSZ treatment affected the functional role of the CD44v9-xCT system and ROS production. Furthermore, the greater production of ROS was observed in MBT-2V cells treated with 300 or 400 μmol/L SSZ ( Figure 2D ).
| Effects of the combination of SSZ and CDDP on cell proliferation and expression of CD44v9 and phospho-p38 MAPK in MBT-2V cells
We examined whether SSZ enhances the cytotoxic effects of CDDP in MBT-2V cells. As shown in Figure 2E , relative cell viability in MBT-2V cells treated with the combination of 300 μmol/L SSZ and 10 μmol/L CDDP was 40.7 ± 3.1%, which was significantly lower than that in MBT-2V cells treated with SSZ alone (83.1 ± 5.4%, P < .001) or CDDP alone (69.8 ± 3.0%, P < .001). The CI value of the SSZ and CDDP combination treatment was 0.88 ± 0.11, which exerted a synergistic effect against MBT-2V cells. We then analyzed CD44v9, phospho-p38 MAPK , and total However, no significant differences were noted in total p38 MAPK protein expression among the 4 groups.
| Antitumor effects of the combination of SSZ with or without CDDP in the murine lung metastasis model
In the first set of in vivo experiments, the effects of SSZ on survival in the murine lung metastasis model were investigated. The SSZ treatment resulted in an animal survival rate of 58.8% over a 25-day follow-up period, whereas this rate was only 18.8% in the vehicle control group (P = .011; Figure 3A ).
In the second set of in vivo experiments evaluating antitumor responses to SSZ alone, CDDP alone, or their combinations in the murine lung metastasis model, the number of tumor nodules (mean ± SE) on the lung surface in mice treated with the vehicle control was 114.3 ± 37.9, which was significantly higher than that in mice treated with SSZ alone (50.6 ± 19.1, P = .003), those treated with CDDP alone (69.2 ± 30.9, P = .042), and those treated with the combination of SSZ and CDDP (15.5 ± 10.8, P < .001; Figure 3B ). Furthermore, the number of lung tumor nodules in mice treated with the combination of SSZ and CDDP was significantly lower than that in mice treated with SSZ or CDDP alone (P < .001 for each, respectively).
Representative samples are shown in Figure 3C .
In Figure 4A , a histopathological examination of H&E-stained sections showed that lung tumor nodules in mice treated with the vehicle control were more prominent than those in mice treated with SSZ alone, CDDP alone, and their combinations. Lung tumor nodules in mice treated with the combination of SSZ and CDDP were the smallest among the 4 treatment groups. CD44v9 immunohistochemical staining on tumor tissue is also shown in Figure 4B .
The density of CD44v9 (mean ± SE) in lung tumor nodules in mice treated with the vehicle control was 89.6 ± 9.77%, which was significantly higher than that in mice treated with SSZ alone (56.9 ± 17.2%, P = .002), those treated with CDDP alone (75.9 ± 16.8%, P = .034), and those treated with the combination of SSZ and CDDP (36.7 ± 6.33%, P < .001; Figure 4C ).
Regarding the side-effects of SSZ, no abnormal laboratory data were obtained from mice treated with SSZ alone, CDDP alone, or their combinations. We also histologically analyzed the major organs, including the heart, liver, kidneys, spleen, pancreas, and ovaries, using H&E-stained sections. No significant differences were observed in the histological appearance of or damage to these organs among the 4 treatment groups.
| D ISCUSS I ON
In the present study, we examined 63 MIBC patients who under- All data are shown as mean ± SE. *P < .01, **P < .001 tissue samples has also been reported in various cancers, such as gastric, 24 hepatocellular, 25 and head and neck cancers. 26 In the field of urothelial cancer, Miyake et al 12 showed that an elevated ratio of CD44v8-10 to standard CD44 indicated shorter diseasefree survival, and Hagiwara et al 9 reported that the expression of CD44v9 was an independent predictor of tumor recurrence as well as cancer death in muscle invasive upper tract urothelial carcinoma. The initial finding of SSZ as a potent inhibitor of xCT was investigated in lymphoma cells 14 and increasing numbers of studies reported the anticancer effects of SSZ in various cancers, such as glioma, 27 prostate cancer, 28 and pancreatic cancer. 16 Furthermore, SSZ was shown to enhance the therapeutic efficacy of chemotherapies. 21, 29 In the present study, we examined the effectiveness of SSZ in BC cells using the MBT-2V cell line, which has a highly metastatic potential with high CD44v9 expression. CD44v9 was recently found to interact with xCT by combining together on the tumor cell surface. This interaction stabilizes xCT at the cell membrane, thereby promoting the cellular uptake of cysteine and subsequent synthesis of GSH. 8 Glutathione is a major antioxidant that is essential for protecting cells against ROS. Reductions in ROS production inactivate the ROS-p38 MAPK signal, and p38 MAPK is a class of MAPK that nega- The use of female mice in our in vivo study is one of the limitations of the present study. There were several reasons for using female mice, but not male mice. We previously developed and used a metastatic bladder cancer animal model using female mice with high reproducibility. 33 Furthermore, we are undertaking another in vivo study using an MBT-2 orthotopic BC model. Female C3H/HeN mice are suitable for developing the orthotopic BC model due to the ease of catheterization with a short urethra. In addition, previous studies showed that female bladder cancer patients had greater metastatic potential and a poorer prognosis. 34, 35 In summary, the expression of CD44v9 could be a useful clinical biomarker for predicting poor outcomes in MIBC patients.
Sulfasalazine could modulate the CD44v9-xCT system by inhibiting GSH levels, inducing ROS production, and upregulating phospho- 
